[1]AngewandteChemie-InternationalEdition,2019,vol.58,p.15747-15751 Angew.Chem.,2019,vol.131,p.15894-15898,5
Title: Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
Journal: Bioorganic & medicinal chemistry letters 20141001
Title: Synthesis and anticancer activity of oxindole derived imidazo[1,5-a]pyrazines.
Journal: European journal of medicinal chemistry 20110601
Title: Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.
Journal: Bioorganic & medicinal chemistry letters 20110401
Title: Synthesis of substituted imidazo[1,5-a]pyrazines via mono-, di-, and directed remote metalation strategies.
Journal: Organic letters 20091119
Title: Kinase inhibitors for the treatment of inflammatory and autoimmune disorders.
Journal: Purinergic signalling 20090301
Title: A novel synthesis of highly substituted imidazo[1,5-a]pyrazine derivatives by 3-CR/2-CR sequence.
Journal: Molecular diversity 20090201
Title: Palladium-catalyzed direct heck arylation of dual pi-deficient/pi-excessive heteroaromatics. Synthesis of C-5 arylated imidazo[1,5-a]pyrazines.
Journal: Organic letters 20080717
Title: Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Journal: Bioorganic & medicinal chemistry 20080201
Title: Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke.
Journal: Bioorganic & medicinal chemistry 20070115